Multiple myeloma is a cancer formed due to malignant plasma cells. Normal plasma cells are found in the bone marrow and are an important part of the immune system. Plasma cells helps to fight infections by making antibodies that recognize and attack germs. Multiple myeloma causes cancer cells to accumulate in the bone marrow, where they crowd out healthy blood cells. These malignant plasma cells then produce abnormal proteins (m protein) which may cause tumors, damage the kidneys, and impair immune system function.
The global Multiple Myeloma market is anticipated to be mainly driven by increase in ageing population, rising obese population, increase in healthcare expenditure and increased penetration of novel cancer drugs. Some of the significant developments of this industry include upcoming new innovative products in the market, trend of combination therapies, and chance of new players.
In 2018, the global Multiple Myeloma Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Multiple Myeloma Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Multiple Myeloma Treatment development in United States, Europe and China.
The key players covered in this study
Johnson & Johnson
Market segment by Type, the product can be split into
Immunomodulatory Agents (IMiDs)
Histone Deacetylase (HDAC) Inhibitors
Market segment by Application, split into
Cancer Treatment and Rehabilitation Centers
Market segment by Regions/Countries, this report covers
Central & South America
The study objectives of this report are:
To analyze global Multiple Myeloma Treatment status, future forecast, growth opportunity, key market and key players.
To present the Multiple Myeloma Treatment development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Multiple Myeloma Treatment are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.